Valuation: Intervacc AB

Market Cap 43Cr 4.48Cr 3.89Cr 3.64Cr 3.33Cr 6.29Cr 426.89Cr 6.37Cr 17Cr 213.29Cr 17Cr 16Cr 709.9Cr P/E 2026 *
-5.68x
P/E 2027 * -5.68x
Enterprise Value 33Cr 3.5Cr 3.04Cr 2.85Cr 2.6Cr 4.92Cr 333.65Cr 4.98Cr 13Cr 166.7Cr 13Cr 13Cr 554.85Cr EV / Sales 2026 *
18.8x
EV / Sales 2027 * 12.1x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day+3.14%
1 week-2.80%
Current month-1.57%
1 month-3.85%
3 months+10.04%
6 months+36.02%
Current year+35.28%
1 week 1.2
Extreme 1.198
1.3
1 month 1
Extreme 1
1.35
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
84
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
23/02/25 Free

Chief Financial Officer

9,29,208 1.2269%
17/02/25 Buy

Chief Executive Officer

1,35,000 0.1783%
17/02/25 Sell

Chief Executive Officer

2,78,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
+3.14%-2.80%+22.79%-76.15% 4.35Cr
-3.25%+13.72%+52.49%+88.86% 6.49TCr
+0.69%+0.96%+29.39%+68.41% 5.41TCr
-1.07%-1.79%-18.07%-14.36% 2.32TCr
+33.86%+30.60%+19.14%+502.77% 2.15TCr
+6.81%+13.84%+46.90%+0.57% 2.13TCr
-0.79%+1.79%+36.31%-25.84% 1.79TCr
-3.37%+25.85%+213.21%+369.13% 1.7TCr
+3.94%+9.45%+32.44%+667.39% 1.5TCr
-7.94%-6.74%+38.42%+157.52% 1.43TCr
Average +3.21%+5.41%+47.30%+173.83% 2.49TCr
Weighted average by Cap. +2.20%+6.97%+45.37%+152.56%

Financials

2026 *2027 *
Net sales 1.77Cr 18.62L 16.16L 15.13L 13.84L 26.13L 18Cr 26.47L 69.46L 8.86Cr 69.91L 68.39L 29Cr 3Cr 31.61L 27.43L 25.69L 23.5L 44.36L 30Cr 44.94L 1.18Cr 15Cr 1.19Cr 1.16Cr 50Cr
Net income -8.08Cr -84.99L -73.76L -69.07L -63.18L -1.19Cr -81Cr -1.21Cr -3.17Cr -40Cr -3.19Cr -3.12Cr -134.64Cr -8.36Cr -87.99L -76.36L -71.5L -65.41L -1.23Cr -84Cr -1.25Cr -3.28Cr -42Cr -3.3Cr -3.23Cr -139.39Cr
Net Debt -9.3Cr -97.88L -84.94L -79.54L -72.76L -1.37Cr -93Cr -1.39Cr -3.65Cr -47Cr -3.68Cr -3.6Cr -155.06Cr -6.3Cr -66.27L -57.51L -53.85L -49.26L -93L -63Cr -94.21L -2.47Cr -32Cr -2.49Cr -2.43Cr -104.98Cr
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
06/26/06 SEK 1.250 +3.14% 2,20,954
05/26/05 SEK 1.212 -3.96% 4,94,213
04/26/04 SEK 1.262 +3.10% 2,05,987
03/26/03 SEK 1.224 -3.62% 2,85,858
31/26/31 SEK 1.270 -1.24% 2,18,129

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock